AlloVir (ALVR) Competitors $9.63 -0.20 (-2.03%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$9.46 -0.17 (-1.77%) As of 02/21/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALVR vs. FULC, MOLN, CGEN, PLX, PRQR, INBX, CYBN, IVVD, NBTX, and DRUGShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Fulcrum Therapeutics (FULC), Molecular Partners (MOLN), Compugen (CGEN), Protalix BioTherapeutics (PLX), ProQR Therapeutics (PRQR), Inhibrx (INBX), Cybin (CYBN), Invivyd (IVVD), Nanobiotix (NBTX), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Fulcrum Therapeutics Molecular Partners Compugen Protalix BioTherapeutics ProQR Therapeutics Inhibrx Cybin Invivyd Nanobiotix Bright Minds Biosciences AlloVir (NASDAQ:ALVR) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Which has more volatility & risk, ALVR or FULC? AlloVir has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Which has preferable valuation and earnings, ALVR or FULC? Fulcrum Therapeutics has higher revenue and earnings than AlloVir. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlloVirN/AN/A-$190.42M-$20.23-0.48Fulcrum Therapeutics$2.81M74.00-$97.33M-$0.31-12.44 Does the MarketBeat Community prefer ALVR or FULC? Fulcrum Therapeutics received 71 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 61.25% of users gave Fulcrum Therapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote. CompanyUnderperformOutperformAlloVirOutperform Votes2757.45% Underperform Votes2042.55% Fulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Does the media refer more to ALVR or FULC? In the previous week, Fulcrum Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for AlloVir. AlloVir's average media sentiment score of 1.44 beat Fulcrum Therapeutics' score of 0.44 indicating that AlloVir is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AlloVir 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ALVR or FULC? Fulcrum Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 142.11%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is ALVR or FULC more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets AlloVirN/A -71.03% -61.27% Fulcrum Therapeutics N/A -7.31%-6.74% Do insiders and institutionals have more ownership in ALVR or FULC? 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryFulcrum Therapeutics beats AlloVir on 13 of the 16 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.55M$3.13B$5.77B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-0.4830.1126.4618.82Price / SalesN/A386.73453.2580.30Price / CashN/A183.5344.0437.47Price / Book0.333.567.634.64Net Income-$190.42M-$71.72M$3.18B$245.69M7 Day Performance-2.73%-2.46%-1.91%-2.66%1 Month Performance4.67%-0.25%-0.19%-2.15%1 Year Performance-40.30%-12.31%16.70%12.90% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVir3.0316 of 5 stars$9.63-2.0%N/A-41.2%$48.55MN/A-0.48110Positive NewsFULCFulcrum Therapeutics1.8409 of 5 stars$3.69-0.5%$9.33+152.9%-59.6%$199.04M$2.81M-11.90100Upcoming EarningsNews CoverageMOLNMolecular Partners0.135 of 5 stars$4.92flatN/A+8.6%$198.59M$6.00M-2.29180News CoverageGap DownCGENCompugen2.0091 of 5 stars$2.22+1.4%$4.00+80.2%-11.9%$198.11M$33.46M111.0070PLXProtalix BioTherapeutics2.189 of 5 stars$2.69+1.1%$15.00+457.6%+68.3%$198.07M$65.49M-20.69200PRQRProQR Therapeutics1.9617 of 5 stars$2.42+6.6%$8.83+265.0%+34.7%$197.67M$7.05M-7.56180INBXInhibrx1.9167 of 5 stars$13.39+1.9%N/A-67.2%$193.89M$1.63M0.00166Short Interest ↓CYBNCybin2.3276 of 5 stars$9.53+0.6%$111.50+1,070.0%N/A$192.98MN/A-1.4350Gap UpHigh Trading VolumeIVVDInvivyd3.3866 of 5 stars$1.61+16.7%$7.89+389.9%-55.6%$192.58M$11.56M-0.82100Gap UpNBTXNanobiotix2.1396 of 5 stars$4.03-3.1%$12.00+197.8%-40.5%$189.93M$39.18M0.00100DRUGBright Minds Biosciences4.1374 of 5 stars$41.80-8.6%$84.33+101.8%+1,829.8%$185.34MN/A-83.60N/AAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies FULC Alternatives MOLN Alternatives CGEN Alternatives PLX Alternatives PRQR Alternatives INBX Alternatives CYBN Alternatives IVVD Alternatives NBTX Alternatives DRUG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALVR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
